Predicted to enable RNA binding activity. Involved in response to hormone. Part of U1 snRNP and U2 snRNP. Human ortholog(s) of this gene implicated in Prader-Willi syndrome. Orthologous to human SNRPN (small nuclear ribonucleoprotein polypeptide N); INTERACTS WITH 2,4-dinitrotoluene; 6-propyl-2-thiouracil; alachlor.
FE 294; FE 294 psi; FE294; FE294 gene for snRNP-associated polypeptide N; FE294 psi; FE294 psi pseudogene; MGC105406; sm protein D; sm protein N; sm-D; sm-N; small nuclear ribonucleoparticle-associated protein (snRNP) mRNA clone Sm51; small nuclear ribonucleoparticle-associated protein (snRNP) mRNA, clone Sm51; small nuclear ribonucleoprotein N; small nuclear ribonucleoprotein-associated protein N; smN; snRNP-N
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SNRPN mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNRPN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SNRPN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNRPN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SNRPN mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNRPN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of SNRPN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SNRPN mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNRPN mRNA
[NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNRPN mRNA
[perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of SNRPN mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of SNRPN mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNRPN mRNA
Antagonistic effects of retinoic acid and thyroid hormone on the expression of the tissue-specific splicing protein SmN in a clonal cell line derived from rat heart.
Deletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader-Willi syndrome detected by fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q.